Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Eltrombopag - Novartis

Next Previous
X
Search
Drug Profile

Eltrombopag - Novartis

Alternative Names: 497115; Eltrombopag olamine; ETB-115; Promacta; Reboredo; Revolade; SB-497115; SB-497115-GR

Latest Information Update: 25 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ligand Pharmaceuticals
  • Developer French Innovative Leukemia Organisation; GlaxoSmithKline; Groupe Francophone des Myelodysplasies; GSK; Novartis; Technische Universitat Dresden
  • Class Antianaemics; Antineoplastics; Benzoates; Biphenyl compounds; Carboxylic acids; Hydrazines; Pyrazoles; Radioprotectives; Small molecules
  • Mechanism of Action Thrombopoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Aplastic anaemia; Idiopathic thrombocytopenic purpura
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aplastic anaemia; Idiopathic thrombocytopenic purpura; Thrombocytopenia
  • Phase III Acute radiation syndrome
  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes; Transplant rejection
  • Phase I/II Chronic myelomonocytic leukaemia

Most Recent Events

  • 11 Apr 2024 University Children's Hospital Basel in collaboration with Novartis Pharmaceuticals completes a phase II iROM2 trial in Idiopathic thrombocytopenic purpura (Adjunctive treatment, Treatment-naive) in Switzerland (PO) (NCT04812483)
  • 22 Sep 2023 Novartis Pharmaceuticals completes the phase II trial in Idiopathic thrombocytopenic purpura (Newly diagnosed, Combination therapy) in Germany (PO) (NCT04346654)
  • 17 May 2023 Novartis completes a phase II trial in Aplastic anaemia in China (PO) (NCT03988608)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top